Sanofi's Dupixent scores big as the first FDA-approved treatment for eosinophilic esophagitis

Already on a roll, Sanofi and Regeneron’s Dupixent just scored a big FDA win by nabbing a new indication as the first and only medicine approved to treat eosinophilic esophagitis (EoE).

The disease affects more than 160,000 patients in the U.S., who until now have been forced to turn to treatments not specifically approved for the type 2 inflammatory condition.